Author

T. Radivoyevitch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Assay:flow cytometry· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

D. Bayik· 2 shared J. D. Lathia· 2 shared M. A. Vogelbaum· 2 shared M. M. Grabowski· 2 shared T. J. Alban· 2 shared A. Chakraborty· 1 shared A. G. Alvarado· 1 shared A. M. Mohammadi· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Bayik

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Anti-apoptotic Protein in Kidney Cancer

T. M. Grubb, S. Maganti, J. M. Krill-Burger, C. Fraser, L. Stransky, T. Radivoyevitch, K. Sarosiek, F. Vazquez, W. G. Kaelin, A. Chakraborty

The paper identifies a mesenchymal tumor cell state that increases dependency on BCL-XL in kidney cancer, showing anti-tumor efficacy of a BCL-XL inhibitor.

bioRxiv · Jan 29, 2022 · PreprintCancer Biology

Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome

B. Otvos, T. J. Alban, M. M. Grabowski, D. Bayik, E. E. Mulkearns-Hubert, T. Radivoyevitch, a. Rabljenovic, S. Johnson, C. Androjna, A. M. Mohammadi, G. Barnett, M. S. Ahluwalia, M. A. Vogelbaum, P. E. Fecci, J. D. Lathia

The paper develops a mouse model to study how surgery and steroids affect immune responses in glioblastoma, finding systemic lymphocyte reduction and correlations with tumor growth and patient outcomes.

bioRxiv · Aug 12, 2020Cancer Biology

Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network

X. Gu, R. Tohme, B. Tomlinson, M. Hasipek, L. Durkin, C. Schuerger, A. M. Zidan, T. Radivoyevitch, C. Hong, H. Carraway, B. Hamilton, R. Sobecks, B. K. Jha, E. D. Hsi, J. Maciejewski, Y. Saunthararajah

This paper identifies adaptive metabolic responses in pyrimidine metabolism as a mechanism of resistance to decitabine and 5-azacytidine, and shows that alternating these drugs with metabolic inhibitors can extend DNMT1 depletion and delay leukemia relapse.

bioRxiv · Feb 20, 2020Cancer Biology

Global immune fingerprinting in glioblastoma reveals immune-suppression signatures associated with prognosis

T. J. Alban, A. G. Alvarado, M. D. Sorensen, D. Bayik, J. Volovetz, E. Serbinowski, E. Mulkearns-Hubert, M. Sinyuk, J. S. Hale, G. R. Onzi, M. McGraw, P. Huang, M. M. Grabowski, C. A. Wathen, T. Radivoyevitch, , J. D. Lathia

The paper identifies immune-suppression signatures in glioblastoma (GBM) patients, showing elevated myeloid-derived suppressor cells (MDSCs) linked to poor prognosis and reduced survival.

JCI Insight · Nov 2, 2018Peer-reviewedCancer Biology